PK Study of IV Formulation of GW856553

Status:
Completed

Trial end date:
2010-04-15

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers.

Phase 1

GlaxoSmithKline